



BY REGISTERED POST AND BY EMAIL

Attn: Legal Department

Alivus Life Sciences Limited
4th Floor, OIA House
470, Cardinal Gracious Road
Andheri (E), Mumbai 400099

complianceofficer@alivus.com
tushar.mistry@glenmarklifesciences.com
connect@glenmarklifesciences.com

26 May 2025

Notice of Intention to Terminate Nirmatrelvir Licence Agreement

Dear Madam, Sir:

We refer to the Licence Agreement dated 3 March 2022 between the Medicines Patent Pool Foundation (**MPP**) and Glenmark Life Sciences Limited (now known as **Alivus** Life Sciences Limited) relating to the compound nirmatrelvir.

Since July 2024, Alivus has failed to communicate with MPP and has been non-responsive to all of our correspondence. Alivus is in breach of several provisions of the Licence Agreement including, but not limited to, Sections 3.8 and 3.9.

Further, we are aware of significant changes to the legal and/or beneficial ownership of Alivus in March 2024, for which it did not procure the prior written consent of PF PRISM Holdings B.V. (**Pfizer**) and MPP as required under Section 12.3(h) of the Licence Agreement. Alivus also failed to notify MPP of the change of its entity name in January 2025.

MPP is entitled to terminate the Licence Agreement with immediate effect pursuant to Section 12.3(e) and/or Section 12.3(h). Please accept this letter as formal notice that, without any further written notice and unless MPP communicates otherwise in writing in the intervening period, **MPP hereby terminates the Licence Agreement with effect from 27 June 2025.**

We encourage you to contact us prior to the date stipulated above if you would like to discuss our partnership under the Licence Agreement.

MPP otherwise reserves all of its rights under the Licence Agreement and nothing in this letter should be construed as relieving Alivus of its ongoing obligations.

Sincerely

A handwritten signature in blue ink, appearing to read "Chan Park", is written over a blue circular stamp.

Chan Park
General Counsel
Medicines Patent Pool